Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib

Cell and Bioscience

Volumn 5, Issue 1, 2015, Pages

  Xu, Wei ^a,b   Wei, Yunyan ^a   Wu, Shuangshuang ^a   Wang, Yun ^a   Wang, Zhen ^a   Sun, Yu ^c   Cheng, Steven Y ^b   Wu, Jianqing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Origin Bioscience Inc   (China)

Author keywords

EGFR; EMT; Gefitinib; Lung adenocarcinoma; TAZ

Indexed keywords

EID: 85027944721     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/2045-3701-5-7     Document Type: Article

References (36)

1. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA: Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005,37(12):1315-1316. 10.1038/ng1671.
2. Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen J, Rawal B, Fisher KJ, Chen AY, Kitano M, Morita Y, Yamaguchi H, Shibata K, Okabe T, Okamoto I, Nakagawa K, Haura EB: Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 2014,20(15):4059-4074. 10.1158/1078-0432.CCR-13-1559.
3. Suda K, Onozato R, Yatabe Y, Mitsudomi T: EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol 2009,4(1):1-4. 10.1097/JTO.0b013e3181913c9f.
4. Kim Y, Ko J, Cui Z, Abolhoda A, Ahn JS, Ou SH, Ahn MJ, Park K: The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther 2012,11(3):784-791. 10.1158/1535-7163.MCT-11-0750.
5. Mitani A, Nagase T, Fukuchi K, Aburatani H, Makita R, Kurihara H: Transcriptional coactivator with PDZ-binding motif is essential for normal alveolarization in mice. Am J Respir Crit Care Med 2009,180(4):326-338. 10.1164/rccm.200812-1827OC.
6. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB: TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005,309(5737):1074-1078. 10.1126/science.1110955.
7. Zhao B, Tumaneng K, Guan KL: The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011,13(8):877-883. 10.1038/ncb2303.
8. Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S, Cordenonsi M, Piccolo S: Role of TAZ as mediator of Wnt signaling. Cell 2012,151(7):1443-1456. 10.1016/j.cell.2012.11.027.
9. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, Elvassore N, Piccolo S: Role of YAP/TAZ in mechanotransduction. Nature 2011,474(7350):179-183. 10.1038/nature10137.
10. Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS, Yang X: TAZ is a novel oncogene in non-small cell lung cancer. Oncogene 2011,30(18):2181-2186. 10.1038/onc.2010.606.
11. Xie M, Zhang L, He CS, Hou JH, Lin SX, Hu ZH, Xu F, Zhao HY: Prognostic significance of TAZ expression in resected non-small cell lung cancer. J Thorac Oncol 2012,7(5):799-807. 10.1097/JTO.0b013e318248240b.
12. Noguchi S, Saito A, Horie M, Mikami Y, Suzuki HI, Morishita Y, Ohshima M, Abiko Y, Mattsson JS, König H, Lohr M, Edlund K, Botling J, Micke P, Nagase T: An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non-Small Cell Lung Cancer. Clin Cancer Res 2014,20(17):4660-4672. 10.1158/1078-0432.CCR-13-3328.
13. Yang N, Morrison CD, Liu P, Miecznikowski J, Bshara W, Han S, Zhu Q, Omilian AR, Li X, Zhang J: TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle 2012,11(15):2922-2930. 10.4161/cc.21386.
14. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008,105(6):2070-2075. 10.1073/pnas.0709662105.
15. Lau AN, Curtis SJ, Fillmore CM, Rowbotham SP, Mohseni M, Wagner DE, Beede AM, Montoro DT, Sinkevicius KW, Walton ZE, Barrios J, Weiss DJ, Camargo FD, Wong KK, Kim CF: Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J 2014,33(5):468-481. 10.1002/embj.201386082.
16. Lai D, Ho KC, Hao Y, Yang X: Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 2011,71(7):2728-2738. 10.1158/0008-5472.CAN-10-2711.
17. Ji D, Deeds SL, Weinstein EJ: A screen of shRNAs targeting tumor suppressor genes to identify factors involved in A549 paclitaxel sensitivity. Oncol Rep 2007,18(6):1499-1505.
18. Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, Gangeswaran R, Manson-Bishop C, Smith P, Danovi SA, Pardo O, Crook T, Mein CA, Lemoine NR, Jones LJ, Basu S: Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 2008,15(11):1752-1759. 10.1038/cdd.2008.108.
19. Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S: Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res 2010,70(21):8517-8525. 10.1158/0008-5472.CAN-10-1242.
20. Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A, Zhang H, Karlan B, Greene MI, Wang Q: YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene 2013,32(17):2220-2229. 10.1038/onc.2012.231.
21. Touil Y, Igoudjil W, Corvaisier M, Dessein AF, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G, Millet G, Leteurtre E, Dumont P, Truant S, Pruvot FR, Hebbar M, Fan F, Ellis LM, Formstecher P, Van Seuningen I, Gespach C, Polakowska R, Huet G: Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res 2014,20(4):837-846. 10.1158/1078-0432.CCR-13-1854.
22. Bai N, Zhang C, Liang N, Zhang Z, Chang A, Yin J, Li Z, Luo N, Tan X, Luo N, Luo Y, Xiang R, Li X, Reisfeld RA, Stupack D, Lv D, Liu C: Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53. Cancer Biol Ther 2013,14(6):511-520. 10.4161/cbt.24345.
23. Huo X, Zhang Q, Liu AM, Tang C, Gong Y, Bian J, Luk JM, Xu Z, Chen J: Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma. Oncol Rep 2013,29(2):840-846.
24. Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan F, Meng S, Wang Y, Yuan Z, Bi W: SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene 2014,33(11):1468-1474. 10.1038/onc.2013.88.
25. Zhao Y, Khanal P, Savage P, She YM, Cyr TD, Yang X: YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a hippo-independent pathway. Cancer Res 2014,74(16):4493-4503. 10.1158/0008-5472.CAN-13-2712.
26. Lai D, Visser-Grieve S, Yang X: Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep 2012,32(4):361-374. 10.1042/BSR20110125.
27. Chung JH, Rho JK, Xu X, Lee JS, Yoon HI, Lee CT, Choi YJ, Kim HR, Kim CH, Lee JC: Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer 2011,73(2):176-182. 10.1016/j.lungcan.2010.11.011.
28. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL: TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008,28(7):2426-2436. 10.1128/MCB.01874-07.
29. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, Daidone MG, Dupont S, Basso G, Bicciato S, Piccolo S: The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011,147(4):759-772. 10.1016/j.cell.2011.09.048.
30. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY, Guan KL: TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem 2009,284(20):13355-13362. 10.1074/jbc.M900843200.
31. Pobbati AV, Hong W: Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther 2013,14(5):390-398. 10.4161/cbt.23788.
32. Wang MY, Chen PS, Prakash E, Hsu HC, Huang HY, Lin MT, Chang KJ, Kuo ML: Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res 2009,69(8):3482-3491. 10.1158/0008-5472.CAN-08-2524.
33. Tsai HC, Huang CY, Su HL, Tang CH: CTGF increases drug resistance to paclitaxel by upregulating survivin expression in human osteosarcoma cells. Biochim Biophys Acta 2014,1843(5):846-854. 10.1016/j.bbamcr.2014.01.007.
34. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV: An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013,19(1):279-290. 10.1158/1078-0432.CCR-12-1558.
35. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG: Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012,44(8):852-860. 10.1038/ng.2330
36. Meyer AS, Miller MA, Gertler FB, Lauffenburger DA: The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal 2013,6(287):ra66.